Literature DB >> 3263865

Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation.

D H Campen1, D A Horwitz, F P Quismorio, G R Ehresmann, W J Martin.   

Abstract

Levels of interleukin-2 receptors (IL-2R), as measured by a double-antibody "sandwich" enzyme-linked immunosorbent assay technique, were markedly elevated in the serum of patients with systemic lupus erythematosus, rheumatoid arthritis, and bacterial endocarditis, but not in patients with acute gout. Serum levels of IL-2R correlated strongly with clinical and laboratory indicators of disease activity in patients with lupus and in those with rheumatoid arthritis. This relationship was confirmed by sequential determinations in individual patients. Serum IL-2R values correlated with disease activity better than did the Westergren erythrocyte sedimentation rate. Our findings indicate that serum levels of IL-2R may serve as a reliable serologic indicator of disease activity in inflammatory diseases characterized by immune system activation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263865     DOI: 10.1002/art.1780311103

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  39 in total

Review 1.  Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis.

Authors:  B Kirkham
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

2.  Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis.

Authors:  P Airò; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

3.  Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus.

Authors:  P Airŏ; S Braga; E Prati; D Brugnoni; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

4.  Is soluble CD25 antigen (interleukin-2 receptor) a useful parameter for differential diagnosis of thyrotoxicosis?

Authors:  M Hüfner; M Wermann; M Grussendorf; B Heilig
Journal:  Clin Investig       Date:  1992-02

5.  Raised serum levels of CD8, CD25 and beta 2-microglobulin in common variable immunodeficiency.

Authors:  M E North; G P Spickett; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

6.  Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus.

Authors:  M Itoh; Y Goto; Y Ohta; Y Goto; H Ohashi
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

7.  Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course.

Authors:  A J Swaak; R Q Hintzen; V Huysen; H G van den Brink; J T Smeenk
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

8.  Continuity of cytokine activation in patients with familial Mediterranean fever.

Authors:  Sait Bagci; Bulent Toy; Ahmet Tuzun; Yuksel Ates; Murat Aslan; Ali Inal; Mustafa Gulsen; Necmettin Karaeren; Kemal Dagalp
Journal:  Clin Rheumatol       Date:  2004-05-01       Impact factor: 2.980

9.  Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies.

Authors:  E Toussirot; P Lafforgue; J Boucraut; P Despieds; A Schiano; D Bernard; P C Acquaviva
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

10.  Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.

Authors:  K L Lim; A C Jones; N S Brown; R J Powell
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.